Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).

By C. Antoni, A. Kavanaugh, B. Kirkham, Z. Tutuncu, G. Burmester, U. Schneider, D. Furst, J. Molitor, E. Keystone, D. Gladman and 7 more. Arthritis & Rheumatism, 2005

659 citations recorded by the source corpus.

Subfields: Immunology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/b09591aa1fb6d7ac9071f729baaa871fa14dd512